<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://mindmedicinelaw.com/briefing/federal-complaint-triggers-procedural-schedule-for-psychedelic-policy-review-20261119-60145</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:06:51.527082+00:00</news:publication_date><news:title>Federal Complaint Triggers Procedural Schedule for Psychedelic Policy Review</news:title><news:keywords>federal complaint, procedural schedule, psychedelic policy, federal register, regulatory process, legal intervention, research access, enforcement risk, unsealed cases, stakeholder engagement</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/cms-crush-rule-fraud-oversight-and-psychedelic-medicine-access-20261119-60160</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:06:38.735766+00:00</news:publication_date><news:title>CMS CRUSH Rule: Fraud Oversight and Psychedelic Medicine Access</news:title><news:keywords>cms, crush rule, psychedelic medicine, medicare compliance, medicaid fraud, provider enrollment, billing oversight, psychedelic-assisted therapy, healthcare regulation, federal health programs</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/hhs-finalizes-hipaa-rule-changes-impacts-on-psychedelic-research-and-care-20261119-60161</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:06:09.513331+00:00</news:publication_date><news:title>HHS Finalizes HIPAA Rule Changes: Impacts on Psychedelic Research and Care</news:title><news:keywords>hipaa rule change, protected health information, psychedelic clinical trials, care coordination, mental health data, privacy compliance, hhs policy, data sharing, federal register, research protocols</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-intensity-predicts-ketamine-outcomes-new-evidence-20261118-60265</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:05.429339+00:00</news:publication_date><news:title>Psychedelic Intensity Predicts Ketamine Outcomes: New Evidence</news:title><news:keywords>ketamine therapy, psychedelic intensity, depression treatment, subjective experience, clinical outcomes, mindbloom psychedelic intensity scale, telehealth psychiatry, treatment response predictors, psychedelic clinical trials</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/veterans-groups-press-va-congress-on-psychedelic-policy-readiness-20261118-60226</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:06:25.218272+00:00</news:publication_date><news:title>Veterans Groups Press VA, Congress on Psychedelic Policy Readiness</news:title><news:keywords>veterans mental health, psychedelic policy, va infrastructure, fda approval, mdma therapy, psilocybin trials, congressional advocacy, clinical implementation, public health, regulatory planning</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-and-treatment-resistant-depression-clinical-evidence-and-policy-outlo-20261118-59973</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:36.783442+00:00</news:publication_date><news:title>Psilocybin and Treatment-Resistant Depression: Clinical Evidence and Policy Outlook</news:title><news:keywords>psilocybin, depression, treatment-resistant depression, clinical trials, FDA, psychedelic-assisted therapy, policy, anhedonia, mental health, drug development</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/optimi-health-advances-psychedelic-trials-phase-2b-revision-phase-3-plans-us-ind-20261118-59971</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:13.861653+00:00</news:publication_date><news:title>Optimi Health Advances Psychedelic Trials: Phase 2b Revision, Phase 3 Plans, US IND Filings</news:title><news:keywords>optimi health, psychedelic clinical trials, phase 2b amendment, phase 3 planning, us ind filing, fda regulation, adaptive trial design, psychedelic therapeutics, regulatory pathways</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-experience-intensity-and-antidepressant-outcomes-clinical-and-policy-im-20261118-59966</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:00.178820+00:00</news:publication_date><news:title>Ketamine Experience Intensity and Antidepressant Outcomes: Clinical and Policy Implications</news:title><news:keywords>ketamine, psychedelic experience, antidepressant outcomes, clinical trial design, subjective experience, regulatory policy, insurance coverage, psychedelic-assisted therapy, treatment efficacy, mental health</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/pvn-as-central-hub-for-pain-emotion-comorbidity-implications-for-psychedelic-res-20261117-60318</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:19.564226+00:00</news:publication_date><news:title>PVN as Central Hub for Pain-Emotion Comorbidity: Implications for Psychedelic Research</news:title><news:keywords>hypothalamic paraventricular nucleus, pain-emotion comorbidity, crh oxytocin balance, neuropeptide systems, chronic pain, depression and anxiety, psychedelic trial design, neuromodulation, neuroinflammation, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/deep-learning-enhances-calcium-imaging-in-psychedelic-research-20261117-60301</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:05.227479+00:00</news:publication_date><news:title>Deep Learning Enhances Calcium Imaging in Psychedelic Research</news:title><news:keywords>deep learning, calcium imaging, neuronal dynamics, psychedelic research, preclinical studies, convolutional neural networks, data analysis, drug discovery, segmentation-agnostic, neuroscience methods</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/gabaergic-neuron-dysfunction-and-psychiatric-disorders-implications-for-psychede-20261117-60316</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:55.616602+00:00</news:publication_date><news:title>GABAergic Neuron Dysfunction and Psychiatric Disorders: Implications for Psychedelic Research</news:title><news:keywords>gabaergic neurons, psychiatric disorders, cell-type specificity, multi-omic analysis, clinical trial design, psychedelic mechanisms, biomarker discovery, e/i balance, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-s-effects-on-sleep-neurophysiology-in-mdd-aud-new-rct-insights-20261117-60303</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:45.730610+00:00</news:publication_date><news:title>Psilocybin’s Effects on Sleep Neurophysiology in MDD/AUD: New RCT Insights</news:title><news:keywords>psilocybin, sleep neurophysiology, randomized controlled trial, major depressive disorder, alcohol use disorder, sleep eeg, biomarkers, psychedelic therapy, clinical research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/self-transcendent-psychedelic-experiences-distinct-outcomes-in-clinical-research-20261117-60042</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:30.518187+00:00</news:publication_date><news:title>Self-Transcendent Psychedelic Experiences: Distinct Outcomes in Clinical Research</news:title><news:keywords>self-transcendent experiences, psychedelic research, clinical trial design, mindset and intention, psilocybin, MDMA, cannabis, psychological outcomes, therapeutic protocols, risk factors</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/transformative-and-existential-strategies-in-trauma-therapy-insights-for-psyched-20261117-60044</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:31.864226+00:00</news:publication_date><news:title>Transformative and Existential Strategies in Trauma Therapy: Insights for Psychedelic-Assisted Modalities</news:title><news:keywords>trauma therapy, psychedelic-assisted therapy, existential psychotherapy, group therapy, emdr, 3mdr, post-traumatic growth, meaning-making, clinical research, therapist training</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/rapid-acting-antidepressant-effects-of-anesthetic-drugs-clinical-evidence-and-tr-20261117-60077</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:19.381984+00:00</news:publication_date><news:title>Rapid-Acting Antidepressant Effects of Anesthetic Drugs: Clinical Evidence and Translational Gaps</news:title><news:keywords>rapid-acting antidepressants, ketamine, esketamine, treatment-resistant depression, nitrous oxide, anesthetic drugs, mechanisms of action, clinical monitoring, translational research, regulatory policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/multidimensional-self-transcendence-in-psychedelic-therapy-clinical-and-research-20261117-60043</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:07.145992+00:00</news:publication_date><news:title>Multidimensional Self-Transcendence in Psychedelic Therapy: Clinical and Research Implications</news:title><news:keywords>psychedelic therapy, self-transcendent experiences, clinical trial design, positive affect, mindset and intention, harm reduction, therapeutic protocols, ego dissolution, regulatory implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ai-guided-precision-psychedelic-therapies-for-depression-in-taiwan-20261117-60061</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:05:54.430789+00:00</news:publication_date><news:title>AI-Guided Precision Psychedelic Therapies for Depression in Taiwan</news:title><news:keywords>precision psychiatry, treatment-resistant depression, taiwan, ai in mental health, psychedelic therapy, neuroimaging biomarkers, clinical staging, technology transfer, international collaboration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-for-treatment-resistant-depression-clinical-practice-and-policy-in-the--20261117-59972</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:49.236588+00:00</news:publication_date><news:title>Ketamine for Treatment-Resistant Depression: Clinical Practice and Policy in the US</news:title><news:keywords>ketamine, treatment-resistant depression, TRD, off-label use, clinical guidance, FDA, esketamine, psychiatric clinics, policy, safety</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/oregon-psilocybin-home-services-case-legal-boundaries-and-implications-20261117-59974</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:24.628648+00:00</news:publication_date><news:title>Oregon Psilocybin Home Services Case: Legal Boundaries and Implications</news:title><news:keywords>oregon psilocybin law, home-based facilitation, psychedelic regulation, legal precedent, measure 109, oregon health authority, psilocybin access, service delivery models, policy implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/helus-modified-psychedelic-achieves-phase-3-success-in-depression-20261116-60377</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:05:52.833112+00:00</news:publication_date><news:title>Helus' Modified Psychedelic Achieves Phase 3 Success in Depression</news:title><news:keywords>helus, modified psychedelic, phase 3 trial, depression treatment, clinical trial results, intellectual property, regulatory pathways, safety profile, next-generation psychedelics</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/meta-analysis-self-as-dynamic-brain-coalitions-in-psychedelic-neuroscience-20261116-60063</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:07:03.953380+00:00</news:publication_date><news:title>Meta-Analysis: Self as Dynamic Brain Coalitions in Psychedelic Neuroscience</news:title><news:keywords>self-related processing, neuroimaging, psychedelic neuroscience, distributed brain networks, ego dissolution, dynamic connectivity, clinical trial design, biomarkers, FDA guidance</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/meta-analysis-context-and-method-shape-psilocybin-critical-period-findings-20261116-60065</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:56.022066+00:00</news:publication_date><news:title>Meta-Analysis: Context and Method Shape Psilocybin Critical Period Findings</news:title><news:keywords>psilocybin, critical period reopening, context dependence, social reward learning, preclinical research, meta-analysis, clinical trial design, set and setting, methodological rigor, psychedelic neuroscience</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-trials-and-depression-rethinking-evidence-standards-20261116-60079</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:43.749928+00:00</news:publication_date><news:title>Ketamine Trials and Depression: Rethinking Evidence Standards</news:title><news:keywords>ketamine, depression, clinical trials, treatment-resistant depression, patient selection, outcome measures, trial design, psychiatry, evidence-based medicine, risk-benefit</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-alters-neuronal-activity-in-mice-acute-and-lasting-effects-20261116-60064</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:05:40.634588+00:00</news:publication_date><news:title>Psilocybin Alters Neuronal Activity in Mice: Acute and Lasting Effects</news:title><news:keywords>psilocybin, neuroplasticity, neuronal firing, mouse brain, neuropixels probes, psychiatric research, clinical trial design, persistent effects, regulatory policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mdma-assisted-psychotherapy-for-sexual-offending-prevention-trial-proposal-and-i-20261114-60288</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:34.548579+00:00</news:publication_date><news:title>MDMA-Assisted Psychotherapy for Sexual Offending Prevention: Trial Proposal and Implications</news:title><news:keywords>mdma-assisted psychotherapy, sexual offending prevention, paraphilic disorders, clinical trial ethics, public health policy, psychedelic research, regulatory safeguards, ptsd overlap, criminal justice innovation</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/iv-ketamine-for-trd-evidence-and-policy-in-resource-limited-settings-20261114-60083</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:07.461029+00:00</news:publication_date><news:title>IV Ketamine for TRD: Evidence and Policy in Resource-Limited Settings</news:title><news:keywords>iv ketamine, treatment-resistant depression, resource-limited settings, public health policy, generic drugs, hospital procurement, clinical efficacy, esketamine, psychiatric treatment, implementation challenges</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/cost-effectiveness-of-psychedelic-therapies-for-depression-and-ptsd-systematic-r-20261113-60291</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:30.026144+00:00</news:publication_date><news:title>Cost-Effectiveness of Psychedelic Therapies for Depression and PTSD: Systematic Review Insights</news:title><news:keywords>cost-effectiveness, psychedelic-assisted therapy, depression, ptsd, systematic review, health economics, insurance coverage, policy, clinical trials, mental health</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/fda-ends-expedited-review-as-compass-files-psilocybin-nda-20261113-60225</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:05:50.981508+00:00</news:publication_date><news:title>FDA Ends Expedited Review as Compass Files Psilocybin NDA</news:title><news:keywords>fda policy, psychedelic drug approval, compass pathways, psilocybin nda, ibogaine research funding, nih grants, regulatory barriers, clinical trials, treatment-resistant depression</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/desci-and-blockchain-security-vs-openness-in-psychedelic-science-20261112-60074</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:07:18.920200+00:00</news:publication_date><news:title>DeSci and Blockchain: Security vs. Openness in Psychedelic Science</news:title><news:keywords>decentralized science, blockchain, open science, psychedelic research, data governance, tokenized governance, research transparency, community trust, regulatory compliance, decentralized autonomous organizations</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/vr-gameplay-modulates-eeg-complexity-and-ego-dissolution-implications-for-psyche-20261109-60041</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:07:30.362022+00:00</news:publication_date><news:title>VR Gameplay Modulates EEG Complexity and Ego Dissolution: Implications for Psychedelic Neuroscience</news:title><news:keywords>virtual reality, EEG complexity, ego dissolution, flow state, psychedelic neuroscience, altered states, clinical trial design, non-pharmacological interventions</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-metaplasticity-mechanisms-and-persistence-limits-20261108-60058</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:19.879154+00:00</news:publication_date><news:title>Psychedelic Metaplasticity: Mechanisms and Persistence Limits</news:title><news:keywords>psychedelic metaplasticity, 5-HT2A receptor, epigenomic priming, histone acetylation, persistent effects, clinical translation, mechanistic research, regulatory science</news:keywords></news:news></url></urlset>